Prmt Inhibitor Assay
Prmt Inhibitor Assay - Related Videos
09:11
Assays for Validating Histone Acetyltransferase Inhibitors
0 Views •
Cited by 6 •
2020
Inhibitors of histone acetyltransferases (HATs, also known as lysine acetyltransferases), such as CBP/p300, are potential therapeutics for treating cancer. However, rigorous methods for validating these inhibitors are needed. Three in vitro methods for validation include HAT assays with recombinant acetyltransferases, immunoblotting for histone acetylation in cell culture, and ChIP-qPCR.
03:47
Screening Inhibitors of Bacterial Membrane-Bound Pyrophosphatase Using a Colorimetric Assay
0 Views •
2025
Source: Vidilaseris, K., et al. Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors. J. Vis. Exp. (2019)This video demonstrates a colorimetric assay to screen inhibitors of bacterial membrane-bound pyrophosphatase (mPPase) by quantifying orthophosphate release. The method enables identification of compounds that inhibit mPPase from Thermotoga maritima, a potential antimicrobial drug target.
09:31
Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
0 Views •
Cited by 56 •
2017
We describe the use of a phenotypic fluorescence-based neuraminidase inhibition assay to assess the susceptibility of influenza A and B viruses to the neuraminidase inhibitor class of antivirals.
03:29
Synthesis and Assay of Vibrio Quorum Sensing Inhibitors
0 Views •
2024
Thiophenesulfonamide compounds are potent and specific inhibitors of Vibrio quorum sensing regulators LuxR/HapR that block their activity in vivo, thus preventing transcription of genes for virulence, motility, and biofilms. This protocol details how these compounds are synthesized, modeled in silico, and assayed in vivo for activity against LuxR/HapR.
01:52
Eukaryotic Transcription Inhibitors
0 Views •
2020
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells. Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
FAQs
The assay follows PRMT-catalyzed transfer of a methyl group from S-adenosyl-L-methionine to arginine residues on a protein or peptide substrate. When a test compound blocks this reaction, less methylated product forms than in an untreated control. Measuring that difference connects the compound’s effect directly to reduced enzymatic activity under the assay conditions.
The protein or peptide supplies the arginine residues that can receive methyl groups, while S-adenosyl-L-methionine provides the methyl group transferred during the reaction. Including both components allows the assay to represent the core catalytic event carried out by PRMT. Their presence makes product formation a relevant readout for comparing inhibitor effects.
Biochemical measurements show whether a compound reduces PRMT activity in a defined reaction containing enzyme, substrate, and methyl-group donor. Cellular methylation signals instead indicate whether treatment changes methylation within cells. Comparing these formats helps distinguish direct effects observed in a controlled reaction from activity detected in a biological setting, where the result reflects cellular context.
Untreated controls provide the reference level for product formation or cellular methylation signals in the absence of the test compound. Researchers compare treated samples with this baseline to determine how strongly PRMT-associated activity has been reduced. Without that comparison, a measured signal cannot be interpreted clearly as inhibition relative to normal assay or cellular conditions.
A basic workflow establishes the relevant PRMT reaction or cellular system, introduces the compound, and measures either methylated product formation or a cellular methylation signal. Researchers then compare the result with an untreated control to estimate inhibitory effectiveness. This workflow supports initial screening and subsequent characterization of compounds that alter PRMT activity.
PRMTs regulate protein function and gene expression, so altered methylation can provide a way to investigate biological regulation and signaling. In cancer research, these assays help identify and characterize compounds that affect PRMT activity and prioritize promising inhibitors for further biological or therapeutic studies. The results can also support investigation of disease mechanisms involving methylation control.